quinazolines has been researched along with Cells, Neoplasm Circulating in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (12.90) | 29.6817 |
| 2010's | 25 (80.65) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Asokan, N; Bahram, S; Busnelli, I; Carapito, R; Follain, G; Garcia-Leon, MJ; Gensbittel, V; Goetz, JG; Larnicol, A; Lefebvre, O; Mercier, L; Osmani, N; Paul, N; Pichot, A | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Chen, M; Tong, B; Wang, M; Xing, J; Xu, Y; Zhao, J; Zhong, W | 1 |
| Cao, J; Chen, Y; Cui, Y; Jiang, N; Jiang, W; Ke, Z; Lei, Y; Sun, Y; Wang, H; Wang, Y; Xu, D; Zhang, Y | 1 |
| Anthoney, A; Backen, AC; Beare, S; Bridgewater, JA; Corrie, PG; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; McNamara, MG; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Elinoff, JM; Kleiner, DE; Lee, JM; Peer, CJ; Pratt, D; Solomon, MA; Suffredini, DA | 1 |
| Burton, L; Cowan, KJ; Hampton, GM; Hegde, PS; Lackner, MR; Li, C; Merchant, M; Parab, V; Patel, P; Penuel, E; Peterson, A; Yauch, RL | 1 |
| Avery, M; Coombes, RC; Di Leo, A; Frampton, AE; Krell, J; Payne, R; Pestrin, M; Reise, J; Stebbing, J; Woodley, L | 1 |
| Bachelot, T; Bidard, FC; Campone, M; Cropet, C; Curé, H; Dalenc, F; Dômont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Mahier Aït-Oukhatar, C; Pierga, JY; Romieu, G; Tresca, P | 1 |
| Aura, CM; Azim, HA; Baselga, J; Bavington, M; Cure, H; de Azambuja, E; Di Cosimo, S; Domont, J; Eidtmann, H; Ellis, C; Ferro, A; Gamez, C; Gebhart, G; Ignatiadis, M; Maetens, M; Piccart-Gebhart, M; Rothé, F; Rouas, G; Sotiriou, C; Toral-Peña, JC; Vuylsteke, P | 1 |
| Agelaki, S; Georgoulias, V; Kallergi, G; Kalykaki, A; Mavroudis, D; Xyrafas, A | 1 |
| Anderes, K; Camacho, LH; Culotta, KS; Davis, DW; Ekmekcioglu, S; Falchook, GS; Fu, S; Garrido-Laguna, I; George, GC; Hong, DS; Kurzrock, R; Liu, W; Moulder, SL; Naing, A; Percy Ivy, S; Piha-Paul, S; Tsimberidou, AM; Wen, Y; Wheler, JJ | 1 |
| Brandes, AA; Buttitta, F; Centi, I; Chella, A; Crinò, L; Cuccurullo, F; De Pas, T; Del Grammastro, M; Felicioni, L; Filice, G; Malatesta, S; Marchetti, A; Santoro, A; Venturino, P | 1 |
| Agelaki, S; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kallergi, G; Kalykaki, A; Markomanolaki, H; Mavroudis, D; Papadaki, MA | 1 |
| Alunni-Fabbroni, M; de Gregorio, N; Fehm, T; Friedl, TW; Hartkopf, A; Huober, J; Janni, W; Meier-Stiegen, F; Müller, V; Pantel, K; Rack, B; Schneeweiss, A; Schochter, F; Scholz, C; Schramm, A; Taran, FA; Trapp, E; Wallwiener, D | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Batra, S; Batra, U; Dhiman, A; Doval, DC; Suresh, P; Talwar, V | 1 |
| Fusi, A; Keilholz, U; Liu, Z; Schmittel, A; Schneider, A; Tinhofer, I | 1 |
| Hatake, K; Ito, Y; Iwase, T | 1 |
| Alvarez, RH; Cristofanilli, M; De Giorgi, U; De Laurentiis, M; De Placido, S; Giordano, A; Giuliano, M; Handy, BC; Hess, KR; Hortobagyi, GN; Jackson, S; Mego, M; Reuben, JM; Ueno, NT; Valero, V | 1 |
| Crane, K | 1 |
| Battelli, N; Bessi, S; Biganzoli, L; Buyse, M; Coombes, CR; Di Leo, A; Di Marsico, R; Gianni, L; Gori, S; Masci, G; Minisini, AM; Pestrin, M; Puglisi, F; Ravaioli, A; Stebbing, J; Tondini, C | 1 |
| Amler, LC; Atwal, S; Fine, BM; Hampton, GM; Hicks, RJ; Hughes, BG; Lackner, MR; Liu, W; Pirzkall, A; Punnoose, EA; Raja, R | 1 |
| Dong, M; Pampo, C; Shi, W; Siemann, DW | 1 |
| Bevilacqua, S; Botti, G; Caraco, C; Caronna, A; Costanzo, R; De Lutio, E; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rocco, G; Sandomenico, C | 1 |
| Hotta, K; Kanehiro, A; Kishino, D; Kiura, K; Nishii, K; Notohara, K; Tabata, M; Tanimoto, M; Tanimoto, Y; Ueoka, H; Umemura, S | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Ancukiewicz, M; Batchelor, TT; Benner, T; Cahill, DP; Chen, PJ; Cohen, KS; di Tomaso, E; Drappatz, J; Duda, DG; Ivy, P; Jain, RK; Kozak, KR; Loeffler, JS; Louis, DN; Mrugala, MM; Plotkin, S; Scadden, DT; Sorensen, AG; Wen, PY; Zhang, WT; Zhu, M | 1 |
| de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P | 1 |
| Ambrus, CM; Ambrus, JL; Gastpar, H | 1 |
2 review(s) available for quinazolines and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Design; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
16 trial(s) available for quinazolines and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Keratin-18; Male; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Quinazolines; Treatment Outcome; United Kingdom; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
Topics: Adult; Aged; Breast Neoplasms; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2 | 2013 |
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2013 |
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab; Young Adult | 2013 |
Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Microscopy, Fluorescence; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Quinazolines | 2014 |
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cerebral Hemorrhage; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Neoplastic Cells, Circulating; Quinazolines; Sarcoma; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Topics: Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2014 |
Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cell Count; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Postmenopause; Premenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Survival Analysis; Treatment Outcome | 2015 |
Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lapatinib; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplastic Cells, Circulating; Phenotype; Quality of Life; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
Ongoing Clinical Trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Peptide Fragments; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Young Adult | 2016 |
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2012 |
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Quinazolines | 2012 |
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Topics: Brain Edema; Brain Neoplasms; Chemokine CXCL12; Chemokines, CXC; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factors; Flow Cytometry; Glioblastoma; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Analysis | 2007 |
13 other study(ies) available for quinazolines and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Impairing flow-mediated endothelial remodeling reduces extravasation of tumor cells.
Topics: Animals; Animals, Genetically Modified; Blood Flow Velocity; Embryo, Nonmammalian; Endothelium, Vascular; Gene Expression Regulation, Neoplastic; Gene Ontology; Hemorheology; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Intravital Microscopy; Microfluidics; Microscopy, Confocal; Neoplastic Cells, Circulating; Quinazolines; RNA, Neoplasm; Signal Transduction; Sunitinib; Transendothelial and Transepithelial Migration; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Zebrafish | 2021 |
Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Count; Crizotinib; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Rearrangement; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Prognosis; Quinazolines | 2018 |
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Male; Microarray Analysis; Middle Aged; Mutation; Nanofibers; Neoplastic Cells, Circulating; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Reproducibility of Results | 2018 |
Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab.
Topics: Antibodies, Monoclonal; Autopsy; Carcinoma, Squamous Cell; Fatal Outcome; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Pulmonary Veno-Occlusive Disease; Quinazolines; Thrombotic Microangiopathies; Uterine Cervical Neoplasms | 2018 |
Gallbladder cancer with tumor thrombus in the superior vena cava.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Female; Fibrinolytic Agents; Gallbladder Neoplasms; Gefitinib; Humans; Incidental Findings; Middle Aged; Neoplastic Cells, Circulating; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Superior | 2010 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorouracil; Gene Expression Profiling; Genetic Markers; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2010 |
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Predictive Value of Tests; Prognosis; Quinazolines; Trastuzumab | 2011 |
Elucidating an uncommon disease: inflammatory breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diagnosis, Differential; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Inflammatory Breast Neoplasms; Lapatinib; Mastitis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Quinazolines; Receptor, ErbB-2; Remission Induction; Taxoids; Transforming Growth Factor beta; Trastuzumab; Treatment Outcome | 2011 |
Src-signaling interference impairs the dissemination of blood-borne tumor cells.
Topics: Animals; Benzodioxoles; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases | 2012 |
Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Prognosis; Quinazolines | 2012 |
Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Quinazolines | 2005 |
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
Effect of imidazoquinazolinones on tumor cells in the circulation.
Topics: Animals; Antineoplastic Agents; Fibrinolytic Agents; Male; Mice; Mice, Inbred ICR; Neoplastic Cells, Circulating; Platelet Aggregation; Quinazolines | 1986 |